"Bud\u00EDkov\u00E1, Marie" . "Posp\u00ED\u0161il, Petr" . "8"^^ . "Sl\u00E1vik, Marek" . "adjuvant chemoradiation; gastric cancer; early toxicity; late toxicity; survival outcomes"@en . "Slavikova, M." . "RIV/00216224:14110/14:00077947" . . "Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience"@en . . "Gombosova, J." . "Neoplasma" . . . . "0028-2685" . . "Navr\u00E1tilov\u00E1, P." . . . . . . "61" . . "[A648218524EF]" . "10.4149/neo_2014_090" . . "Surgical resection is the mainstay of gastric or gastroesophageal junction cancer treatment and has curative potential for patients with early-stage disease. In order to improve the poor survival rates, there are two complementary treatment strategies used at most - perioperative chemotherapy based on UK Magic trial or adjuvant chemoradiation based on INT-0116 trial. Daily treatment decision making should be led also by institutional experiences with toxicity evaluation. We evaluated survival and toxicity outcomes of 47 consecutive patients who underwent adjuvant chemoradiation in our institution in the years 2006-2009. 45Gy in 5 weeks with concurrent two cycles of FUFA Mayo regimen chemotherapy were administrated as part of combined treatment. The acute toxicity was relatively mild (CTCAE scale): grade 2 nausea in 26%, vomiting in 13%, and diarrhoea grade 1 in 15% and general abdominal discomfort in 57% of patients. Grade 3 haematological and infectious complications in 6% and 2% respectively."@en . "Burko\u0148, Petr" . "I, P(ED1.100/02/0123), P(ED2.1.00/03.0101)" . "000345950900013" . "14110" . "\u0160lampa, Pavel" . . "SK - Slovensk\u00E1 republika" . "50857" . "6" . "Dvorakova, E." . . "Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience" . . "Kazda, Tom\u00E1\u0161" . . "Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience" . . "Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience"@en . "10"^^ . . . . . . "RIV/00216224:14110/14:00077947!RIV15-MSM-14110___" . "6"^^ . "Surgical resection is the mainstay of gastric or gastroesophageal junction cancer treatment and has curative potential for patients with early-stage disease. In order to improve the poor survival rates, there are two complementary treatment strategies used at most - perioperative chemotherapy based on UK Magic trial or adjuvant chemoradiation based on INT-0116 trial. Daily treatment decision making should be led also by institutional experiences with toxicity evaluation. We evaluated survival and toxicity outcomes of 47 consecutive patients who underwent adjuvant chemoradiation in our institution in the years 2006-2009. 45Gy in 5 weeks with concurrent two cycles of FUFA Mayo regimen chemotherapy were administrated as part of combined treatment. The acute toxicity was relatively mild (CTCAE scale): grade 2 nausea in 26%, vomiting in 13%, and diarrhoea grade 1 in 15% and general abdominal discomfort in 57% of patients. Grade 3 haematological and infectious complications in 6% and 2% respectively." . .